Latest Hotspot

Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy

2 September 2023
3 min read

Recently, Bristol Myers Squibb has announced the latest long-term follow-up results of two Phase 3 studies that assessed the treatment efficacy of Camzyos (mavacamten) on symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. 

Mavacamten is a selective Cardiac myosin conformer inhibitor developed by Bristol Myers Squibb. It reduces the ATPase activity of the cardiac myosin heavy chain, inhibits the excessive formation of myosin-actin cross-links, and induces the entire myosin to transition into a super relaxed state. Consequently, it prevents excessive myocardial contraction and improves diastolic compliance and energy metabolism. In April 2022, mavacamten received FDA approval for the treatment of symptomatic Class II-III obstructive HCM in adult patients to improve their cardiac function and symptoms. Currently, mavacamten has obtained marketing approval from regulatory authorities in Australia, Canada, Brazil, Switzerland, Macau, China, and Singapore.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The results of two phase 3 studies showed that with the extension of follow-up time, Camzyos continued to reduce the proportion of patients needing to undergo invasive septal reduction therapy (SRT) at 56 weeks. The cumulative analysis of up to 120 weeks showed persistent improvement in LVOT obstruction, symptoms, and NT-proBNP levels in symptomatic oHCM patients, with no new safety signals observed.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. 

图形用户界面, 应用程序, Teams

描述已自动生成

According to information disclosed from the Synapse database, as of September 1, 2023, there are a total of 17 drugs under research targeting Cardiac myosin, with 15 intended indications, 17 research institutions involved, 71 related clinical trials, and as many as 1100 patents.Hypertrophic cardiomyopathy (HCM) is a common monogenic hereditary disease in clinical practice, with an incidence rate of about 0.2%. It is hoped that mavacamten can be approved as soon as possible, bringing new treatment options for patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
Latest Hotspot
3 min read
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
2 September 2023
Recently, Roche announced that its PD-L1 targeted antibody, Tecentriq(atezolizumab), has been approved for marketing in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
Read →
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
Latest Hotspot
4 min read
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
2 September 2023
the combined therapy of KRAS G12D inhibitor MRTX1133 and immune checkpoint inhibitors can cause sustained tumor elimination and significantly improve the survival outcomes in mice.
Read →
FibroGen's CTGF antibody Pamrevlumab failed in phase III clinical trials for DMD treatment
Latest Hotspot
3 min read
FibroGen's CTGF antibody Pamrevlumab failed in phase III clinical trials for DMD treatment
2 September 2023
On August 29, FibroGen announced that the CTGF antibody Pamrevlumab for the treatment of Duchenne Muscular Dystrophy (DMD) in the phase three LELANTOS clinical trial did not achieve its primary NSAA endpoint and crucial secondary endpoints.
Read →
The Mechanism of Interferons Antiviral Action and Its Biological Activity
Advanced Tech.
5 min read
The Mechanism of Interferons Antiviral Action and Its Biological Activity
2 September 2023
Interferon (IFN) is a type of crucial cytokine, capable of directly participating in the antiviral immune response of epithelial cells, mediating the natural immune response to induce the expression of Interferon Stimulated Genes (ISG), hence, swiftly establishing the body's natural immune defense line against viral infections.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.